Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 62 (1) , 56-63
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Reduction of Hepatitis B Surface Antigen Levels And Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients Receiving 10 Years of Nucleoside Analogue TherapyHepatology, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide AnaloguesAntiviral Therapy, 2011
- 740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARSJournal of Hepatology, 2011
- Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavirHepatology, 2011
- The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis BHepatology International, 2009
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Hepatology, 2009
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †Hepatology, 2009
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004